Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study
Jasper Therapeutics, Inc. reported positive preliminary results from its ETESIAN Phase 1b study of briquilimab in adults with allergic asthma. A single subcutaneous dose led to significant reductions in sputum eosinophils and improvements in FEV1. The drug was well tolerated, showing a favorable safety profile, supporting its continued development as a potential asthma treatment.
Add 
as your preferred news source on Google
Add Now
Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, on Tuesday reported encouraging preliminary data from its ETESIAN Phase 1b study of subcutaneous briquilimab in adults with allergic asthma.
A single subcutaneous dose of briquilimab led to substantial reductions in sputum eosinophils at six and twelve weeks, along with improvements in FEV1 in both Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR). Significant reductions in serum tryptase were also observed, consistent with findings from other briquilimab studies at the 180mg dose.
Briquilimab was well tolerated, showing a favorable safety profile. The preliminary results support the continued development of briquilimab as a potential treatment for asthma.
For comments and feedback contact: editorial@rttnews.com
Business News
